Stellantis Announces Changes in Leadership Team

Stellantis Announces Changes in Leadership Team

AMSTERDAM, September 28, 2023 – Stellantis today announced the following organizational changes, effective November 1st, 2023.

Emanuele
Cappellano is appointed Chief Operating Officer of Stellantis South America, replacing Antonio Filosa. He previously served as South America Chief Financial Officer for the Company from 2017 to 2021, and currently serves as North America CEO & Group Strategy and Corporate Development Director at Marcolin Group since October 2021.

Antonio
Filosa is appointed Jeep Brand CEO, replacing Christian Meunier who will take a long break to focus on personal interests.

Ashwani
Muppasani, currently China National Sales Company head since July 2022, is appointed Chief Operating Officer of Stellantis India & Asia Pacific, replacing Carl Smiley who has decided to prioritize his private life.

“I want to take the opportunity to warmly thank Christian and Carl for their commitment and contributions to making Stellantis the leading company it is today,” said Stellantis CEO Carlos Tavares. “The circumstances of life must make us accept the personal decisions of our colleagues, as they illustrate their human qualities, beyond their business acumen. I have every confidence that Emanuele and Ashwani, as newly appointed EVPs, as well as Antonio in his new Jeep Brand CEO role, will continue the paths traced by their predecessors and further drive Stellantis to win during this time of profound change in our sector.”

# # #


About Stellantis


Stellantis


N.V.

(NYSE: STLA / Euronext Milan: STLAM / Euronext Paris: STLAP
) is one of the world

s leading automakers and a mobility provider
. Its
storied and iconic brands embody the passion of their visionary founders and today’s customers in their innovative products and services, including Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, Fiat, Jeep

®

, Lancia, Maserati, Opel, Peugeot, Ram, Vauxhall, Free2move and Leasys. Powered by our diversity, we lead the way the world moves – aspiring to become the greatest sustainable mobility tech company, not the biggest, while creating added value for all stakeholders as well as the communities in which it operates. For more information, visit

www.stellantis.com

.

 

 

 

@Stellantis

 

Stellantis

 

Stellantis

 

Stellantis

 

For more information, contact:

Bertrand BLAISE +33 6 33 72 61 86 – [email protected]

 

[email protected]
www.stellantis.com

 

 

Attachment



Lightspeed Welcomes Culinary Titan Joël Robuchon International

From Dubai to Miami to Shanghai, JRI and Lightspeed join forces to deliver elevated dining experiences around the world

Montreal, Sept. 28, 2023 (GLOBE NEWSWIRE) — Lightspeed Commerce Inc. (NYSE | TSX: LSPD) is thrilled to announce that it has entered into a preferred partnership with the iconic Joël Robuchon International group of restaurants. Powering the world’s best businesses, Lightspeed is the unified POS and payments platform for ambitious entrepreneurs to accelerate growth, provide the best customer experiences and become a go-to destination in their space.

It’s no secret that every JRI location runs like a well-oiled machine. To match that exceptional level of service, JRI needed a  global unified payments and point of sale solution that could deliver exceptional results at their restaurants, no matter where they’re located around the world. Insert Lightspeed: the cloud-based platform with the necessary global presence and powerful insights—not to mention singular flexibility—that fit JRI’s vision.

Lightspeed and JRI share the same core principles: excellence, simplicity and consistency. As the late Chef Robuchon said, “To make a grand meal, you have to make it simple.  To look simple is very complicated.  You need the highest quality products, the best equipment and you have to keep the focus on the original flavor of the product.”  Whether guests are enjoying an unforgettable experience in one of JRI’s new unique concepts, having an elegant meal at an illustrious L’Atelier Robuchon or making a quick stop at a sophisticated Deli Robuchon, Lightspeed’s platform brings a simple, seamless experience to staff and customers.

“I grew up watching Joël Robuchon’s cooking shows. This is incredible. It’s such an honor,” said JP Chauvet, Lightpseed’s CEO. “Chef Robuchon built an empire. His restaurants were awarded 31 Michelin stars. It’s still a world record. His whole cooking philosophy—centered on the customer—echoes Lightspeed’s mission to deliver something that appears to be simple but is, in fact, incredibly complex.”

“As we continue to expand to multiple locations around the world it is essential for our future success that we partner with a company like Lightspeed to ensure we customize, streamline and effectively manage all our locations,” said Richard Clark, CEO at JRI. “I am personally very excited to be partnering globally with Lightspeed and look forward to a successful, collaborative partnership.”

JRI joins a growing list of Michelin-starred restaurants using Lightspeed to deliver unparalleled dining experiences, including Alinea (Chicago), Clover Hill (New York), Zilte (Antwerp), Le Chalet de la Forêt (Brussels), Restaurant 212 (Amsterdam), Kei (Paris), Anne Sophie Pic (Lausanne), JAN (Munich) and Da Terra (London).

Dive into Lightspeed Restaurant’s transformative features at lightspeedhq.com.

About Lightspeed 

Powering the businesses that are the backbone of the global economy, Lightspeed’s one-stop commerce platform helps merchants innovate to simplify, scale and provide exceptional customer experiences. Our cloud commerce solution transforms and unifies online and physical operations, multichannel sales, expansion to new locations, global payments, financial solutions and connection to supplier networks.

Founded in Montréal, Canada in 2005, Lightspeed is dual-listed on the New York Stock Exchange and Toronto Stock Exchange (NYSE: LSPD) (TSX: LSPD). With teams across North America, Europe and Asia Pacific, the company serves retail, hospitality and golf businesses in over 100 countries.

For more information, see lightspeedhq.com.

Follow us on social media: LinkedIn, Facebook, Instagram, YouTube, and Twitter.

About JRI

JRI has inherited a priceless legacy. The mission of the Group is clear – to uphold Robuchon’s core beliefs of Excellence, Simplicity, and Consistency in every culinary endeavor. Over the years Robuchon mentored countless chefs. Today many of these chefs remain the bannermen of the Robuchon spirit, dedicated to actively promoting existing concepts whilst actively developing new ones.

Forward-Looking Statements

This news release may include forward-looking information and forward-looking statements within the meaning of applicable securities laws (“forward-looking statements”). Forward-looking statements are statements that are predictive in nature, depend upon or refer to future events or conditions and are identified by words such as “will”, “expects”, “anticipates”, “intends”, “plans”, “believes”, “estimates” or similar expressions concerning matters that are not historical facts. Such statements are based on current expectations of Lightspeed’s management and inherently involve numerous risks and uncertainties, known and unknown, including economic factors. A number of risks, uncertainties and other factors may cause actual results to differ materially from the forward-looking statements contained in this news release, including, among other factors, those risk factors identified in our most recent Management’s Discussion and Analysis of Financial Condition and Results of Operations, under “Risk Factors” in our most recent Annual Information Form, and in our other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedarplus.ca and on EDGAR at www.sec.gov. Readers are cautioned to consider these and other factors carefully when making decisions with respect to Lightspeed’s subordinate voting shares and not to place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are not guarantees of future performance and, while forward-looking statements are based on certain assumptions that Lightspeed considers reasonable, actual events and results could differ materially from those expressed or implied by forward-looking statements made by Lightspeed. Except as may be expressly required by applicable law, Lightspeed does not undertake any obligation to update publicly or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

For further information: Media Contacts: Canada: Victoria Baker, NKPR – [email protected]; USA: Jennifer Fugel, Newsmaker Group- [email protected]; Lightspeed Media Relations – [email protected]; Investor Relations: Gus Papageorgiou, Lightspeed Investor Relations – [email protected]



Sara Basdeo
Lightspeed Commerce Inc.
6475376271
[email protected]

Lightspeed Welcomes Culinary Titan Joël Robuchon International

From Dubai to Miami to Shanghai, JRI and Lightspeed join forces to deliver elevated dining experiences around the world

MONTREAL, Sept. 28, 2023 (GLOBE NEWSWIRE) — Lightspeed Commerce Inc. (NYSE | TSX: LSPD) is thrilled to announce that it has entered into a preferred partnership with the iconic Joël Robuchon International group of restaurants. Powering the world’s best businesses, Lightspeed is the unified POS and payments platform for ambitious entrepreneurs to accelerate growth, provide the best customer experiences and become a go-to destination in their space.

It’s no secret that every JRI location runs like a well-oiled machine. To match that exceptional level of service, JRI needed a global unified payments and point of sale solution that could deliver exceptional results at their restaurants, no matter where they’re located around the world. Insert Lightspeed: the cloud-based platform with the necessary global presence and powerful insights—not to mention singular flexibility—that fit JRI’s vision.

Lightspeed and JRI share the same core principles: excellence, simplicity and consistency. As the late Chef Robuchon said, “To make a grand meal, you have to make it simple. To look simple is very complicated. You need the highest quality products, the best equipment and you have to keep the focus on the original flavor of the product.” Whether guests are enjoying an unforgettable experience in one of JRI’s new unique concepts, having an elegant meal at an illustrious L’Atelier Robuchon or making a quick stop at a sophisticated Deli Robuchon, Lightspeed’s platform brings a simple, seamless experience to staff and customers.

“I grew up watching Joël Robuchon’s cooking shows. This is incredible. It’s such an honor,” said JP Chauvet, Lightpseed’s CEO. “Chef Robuchon built an empire. His restaurants were awarded 31 Michelin stars. It’s still a world record. His whole cooking philosophy—centered on the customer—echoes Lightspeed’s mission to deliver something that appears to be simple but is, in fact, incredibly complex.”

“As we continue to expand to multiple locations around the world it is essential for our future success that we partner with a company like Lightspeed to ensure we customize, streamline and effectively manage all our locations,” said Richard Clark, CEO at JRI. “I am personally very excited to be partnering globally with Lightspeed and look forward to a successful, collaborative partnership.”

JRI joins a growing list of Michelin-starred restaurants using Lightspeed to deliver unparalleled dining experiences, including Alinea (Chicago), Clover Hill (New York), Zilte (Antwerp), Le Chalet de la Forêt (Brussels), Restaurant 212 (Amsterdam), Kei (Paris), Anne Sophie Pic (Lausanne), JAN (Munich) and Da Terra (London).

Dive into Lightspeed Restaurant’s transformative features at lightspeedhq.com.


About Lightspeed

Powering the businesses that are the backbone of the global economy, Lightspeed’s one-stop commerce platform helps merchants innovate to simplify, scale and provide exceptional customer experiences. Our cloud commerce solution transforms and unifies online and physical operations, multichannel sales, expansion to new locations, global payments, financial solutions and connection to supplier networks.

Founded in Montréal, Canada in 2005, Lightspeed is dual-listed on the New York Stock Exchange and Toronto Stock Exchange (NYSE: LSPD) (TSX: LSPD). With teams across North America, Europe and Asia Pacific, the company serves retail, hospitality and golf businesses in over 100 countries.

For more information, see lightspeedhq.com.

Follow us on social media: LinkedIn, Facebook, Instagram, YouTube, and Twitter.


About JRI

JRI has inherited a priceless legacy. The mission of the Group is clear – to uphold Robuchon’s core beliefs of Excellence, Simplicity, and Consistency in every culinary endeavor. Over the years Robuchon mentored countless chefs. Today many of these chefs remain the bannermen of the Robuchon spirit, dedicated to actively promoting existing concepts whilst actively developing new ones.


Forward-Looking Statements

This news release may include forward-looking information and forward-looking statements within the meaning of applicable securities laws (“forward-looking statements”). Forward-looking statements are statements that are predictive in nature, depend upon or refer to future events or conditions and are identified by words such as “will”, “expects”, “anticipates”, “intends”, “plans”, “believes”, “estimates” or similar expressions concerning matters that are not historical facts. Such statements are based on current expectations of Lightspeed’s management and inherently involve numerous risks and uncertainties, known and unknown, including economic factors. A number of risks, uncertainties and other factors may cause actual results to differ materially from the forward-looking statements contained in this news release, including, among other factors, those risk factors identified in our most recent Management’s Discussion and Analysis of Financial Condition and Results of Operations, under “Risk Factors” in our most recent Annual Information Form, and in our other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedarplus.ca and on EDGAR at www.sec.gov. Readers are cautioned to consider these and other factors carefully when making decisions with respect to Lightspeed’s subordinate voting shares and not to place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are not guarantees of future performance and, while forward-looking statements are based on certain assumptions that Lightspeed considers reasonable, actual events and results could differ materially from those expressed or implied by forward-looking statements made by Lightspeed. Except as may be expressly required by applicable law, Lightspeed does not undertake any obligation to update publicly or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

For further information: Media Contacts: Canada: Victoria Baker, NKPR – [email protected]; USA: Jennifer Fugel, Newsmaker Group- [email protected]; Lightspeed Media Relations – [email protected]; Investor Relations: Gus Papageorgiou, Lightspeed Investor Relations – [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/052eb1ab-752a-4808-b375-0fa8ab7b8fd3



Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the publication of results from the T3MPO-3 long-term open-label safety trial of IBSRELA® (tenapanor) for irritable bowel syndrome with constipation (IBS-C) in the Journal of Neurogastroenterology and Motility (JNM). The paper, titled “Long-term safety of tenapanor in patients with irritable bowel syndrome with constipation in the T3MPO-3 study,” can be accessed in the current online edition of the publication. IBSRELA, discovered and developed by Ardelyx, has a first-in-class mechanism of action and is approved by the U.S. Food and Drug Administration to treat IBS-C in adults.

In this long-term open-label safety study, tenapanor showed acceptable tolerability with a safety profile consistent with that reported in the prior studies.

“The T3MPO-3 results provide important data on IBSRELA’s safety profile in a longer-term setting,” said David Rosenbaum, Ph.D., chief development officer of Ardelyx. “We are pleased by the publication of these results in this distinguished gastroenterology journal as we continue to grow awareness of IBSRELA as another option for people with IBS-C.”

Anthony Lembo, M.D., Director of Research for Cleveland Clinic’s Digestive Disease & Surgery Institute, added, “These long-term results provide further support for IBSRELA as a valuable treatment option for people with IBS-C. Adults with IBS-C frequently suffer from constipation, abdominal pain, bloating and other symptoms, which has a significant impact on their quality of life. IBSRELA, with its differentiated mechanism of action and clinically validated efficacy and tolerability, provides an important option for these patients seeking relief from their symptoms.”

Patients who completed T3MPO-1 or T3MPO-2, the two Phase 3 trials of tenapanor for IBS-C, were eligible for enrollment in T3MPO-3. The T3MPO-3 trial enrolled a total of 312 patients of which 262 patients completed treatment. Patients received open-label tenapanor 50 mg twice a day for up to an additional 39 (T3MPO-1) or 26 (T3MPO-2) weeks. Ninety patients received ≥52 weeks of tenapanor. Treatment-emergent adverse events (TEAEs) were reported in 117 of the 312 (37.5%) patients in the entire T3MPO-3 population and in 52 of the 90 (57.8%) patients who received ≥52 weeks of tenapanor. Overall, 10.6% of patients experienced diarrhea. TEAEs led to limited discontinuations (13 patients/4.2%) in the entire T3MPO-3 safety population, (11 patients/3.5%) due to diarrhea, (1.7%/1 patient) due to flatulence and abnormal GI sounds. Tenapanor was generally well tolerated with diarrhea being the most commonly reported adverse event.

The article is available online and can be accessed here.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS
IBSRELA is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of IBSRELA in patients 6 years to less than 12 years of age. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age.

CONTRAINDICATIONS

  • IBSRELA is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.
  • IBSRELA is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

WARNINGS AND PRECAUTIONS

Risk of Serious Dehydration in Pediatric Patients

  • IBSRELA is contraindicated in patients below 6 years of age. The safety and effectiveness of IBSRELA in patients less than 18 years of age have not been established. In young juvenile rats (less than 1 week old; approximate human age equivalent of less than 2 years of age), decreased body weight and deaths occurred, presumed to be due to dehydration, following oral administration of tenapanor. There are no data available in older juvenile rats (human age equivalent 2 years to less than 12 years).
  • Avoid the use of IBSRELA in patients 6 years to less than 12 years of age. Although there are no data in older juvenile rats, given the deaths in younger rats and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of IBSRELA in patients 6 years to less than 12 years of age.

Diarrhea

Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients. If severe diarrhea occurs, suspend dosing and rehydrate patient.

MOST COMMON ADVERSE REACTIONS

The most common adverse reactions in IBSRELA-treated patients (incidence ≥2% and greater than placebo) were: diarrhea (16% vs 4% placebo), abdominal distension (3% vs <1%), flatulence (3% vs 1%) and dizziness (2% vs <1%).

INDICATION

IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.

Please see full

Prescribing Information

, including Boxed Warning, for additional risk information.

About Irritable Bowel Syndrome with Constipation (IBS-C)

Irritable bowel syndrome with constipation (IBS-C) is a gastrointestinal disorder characterized by both abdominal pain and altered bowel movements, estimated to affect 12 million people in the U.S. IBS-C is associated with significantly impaired quality of life, reduced productivity, and substantial economic burden.

About IBSRELA for IBS-C

IBSRELA (tenapanor) is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium. By inhibiting NHE3 on the apical surface of the enterocytes, tenapanor reduces absorption of sodium from the small intestine and colon, thus retaining luminal water content, which accelerates intestinal transit time and results in a softer stool consistency. IBSRELA has also been shown to reduce abdominal pain by decreasing visceral hypersensitivity and by decreasing intestinal permeability in animal models. In a rat model of colonic hypersensitivity, tenapanor reduced visceral hyperalgesia and normalized colonic sensory neuronal excitability.

About Ardelyx, Inc.

Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx’s first approved product, IBSRELA® (tenapanor) is available in the United States and Canada. Ardelyx is developing XPHOZAH® (tenapanor), a novel product candidate for the control of serum phosphate in adult patients with chronic kidney disease (CKD) on dialysis who have an inadequate response or intolerance to a phosphate binder therapy, which has completed three successful Phase 3 trials and an additional two Phase 4 open-label trials. Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly Twitter), LinkedIn and Facebook.

Investor and Media Contacts:

Caitlin Lowie
[email protected]

Kimia Keshtbod
[email protected]



Veradigm and On Belay Health Solutions Collaborate to Expand Value-Based Care Solutions to More Primary Care Practices

Veradigm and On Belay Health Solutions Collaborate to Expand Value-Based Care Solutions to More Primary Care Practices

CHICAGO & BOSTON–(BUSINESS WIRE)–Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions and On Belay Health Solutions, the company on a mission to empower primary care practices to succeed in value-based care, announced today a strategic collaboration to support primary care providers in improving patients’ health outcomes while strengthening their practices’ financial foundation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230928380539/en/

The shift from a fee-for-service healthcare delivery model to a value-based care model has significantly changed the way healthcare is delivered and reimbursed in the United States. Veradigm’s innovative solutions help to promote value-based care initiatives for healthcare providers and most importantly, the patients they serve. Through On Belay Health Solutions, Veradigm Network’s primary care physicians (PCP’s) are poised to improve patient outcomes along with their care team experience.

“Veradigm is dedicated to simplifying healthcare with next-generation technology and solutions,” said Tom Langan, President, and Chief Commercial Officer of Veradigm. “By collaborating with On Belay Health Solutions, the Veradigm Network is providing value, strengthening primary care practices.”

On Belay Health Solutions supports independent primary care physicians in their quest to access meaningful value-based contracts and provides the clinical and operational support necessary to succeed and maintain their independence.

“Our vision is to create a sustainable and positive health care experience. This means we need to support primary care teams in doing things differently to realize better health outcomes, team satisfaction and financial resilience,” said Andrew Allison, Co-Founder and Chief Executive Officer of On Belay Health Solutions. “We’re excited to offer our high-touch platform to the thousands of Veradigm Network PCPs, providing a robust, high-touch care management approach to support their successful transition to value-based care, no matter the stage in their journey.”

About Veradigm®

Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions, all working together to transform healthcare insightfully. For more information on Veradigm, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, and YouTube.

About On Belay Health Solutions

On Belay Health Solutions is on a mission to empower primary care providers to deliver the best possible care, while optimizing their financial and operational performance. On Belay supports practices across the country in successfully transitioning to value-based care with solutions that improve patient outcomes and care team experience. Learn more at www.obhs.com.

© 2023 Veradigm Inc. and/or its affiliates. All Rights Reserved.

Investors:

Jenny Gelinas

312-506-1237

[email protected]

Media:

Concetta Rasiarmos

312-447-2466

[email protected]

Olga Eskinazi

[email protected]

KEYWORDS: United States North America Illinois Massachusetts

INDUSTRY KEYWORDS: Software Practice Management Payments General Health Health Data Management Health Technology Technology

MEDIA:

Logo
Logo
Logo
Logo

MAIA Biotechnology Announces Share Repurchase Program

MAIA Biotechnology Announces Share Repurchase Program

CHICAGO–(BUSINESS WIRE)–
MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, today announced that its Board of Directors has approved a share repurchase program with authorization to purchase up to $800,000 of its Class A common stock through September 2024.

“This share repurchase program demonstrates the confidence we have in our market opportunity and our strategy to invest for long-term growth, which we believe is not reflected in the current market valuation,” said Vlad Vitoc, MAIA’s Chief Executive Officer. “By establishing a repurchase plan, we add another tool to our arsenal that can assist with our future financing efforts, enable us to unlock more of the long-term opportunity we see ahead, and drive sustainable value for all stakeholders.”

With a share repurchase program, MAIA may repurchase shares from time to time through various methods, including in open market transactions, in privately negotiated transactions or otherwise, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, in compliance with applicable state and federal securities laws. The timing, as well as the number and value of shares repurchased under the program, will be determined by the Company at its discretion and will depend on a variety of factors, including our assessment of the intrinsic value of the Company’s common stock, the market price of the Company’s common stock, general market and economic conditions, available liquidity, compliance with the Company’s debt and other agreements, applicable legal requirements, the nature of other investment opportunities available to the Company, and other considerations. The Company is not obligated to purchase any shares under the repurchase program, and the program may be suspended, modified, or discontinued at any time without prior notice. The Company expects to fund the repurchases by using cash on hand and expected free cash flow to be generated in the future.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Inquiries

MAIA Biotechnology

Joseph McGuire

Chief Financial Officer

[email protected]

904-228-2603

Investor Relations

[email protected]

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Oncology

MEDIA:

Logo
Logo

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Stem, Inc. (NYSE: STEM) and Encourages Long-Term STEM Investors to Contact the Firm

PHILADELPHIA, Sept. 28, 2023 (GLOBE NEWSWIRE) — Kaskela Law LLC announces that it is investigating Stem, Inc. (NYSE: STEM) on behalf of the company’s long-term investors.

Stem is a provider of energy storage systems. The current company was formed in April 2021 via a business combination with SPAC entity Star Peak Energy Transition Corp. (NYSE: STPK), with Stem as the surviving, publicly traded entity.

Recently a securities fraud complaint was filed against Stem on behalf of certain investors who purchased shares of the company’s stock between December 4, 2020 and April 3, 2023 (inclusive). The complaint alleges that, during that time period, Stem and certain of the company’s executive officers made a series of false and misleading statements to investors about Stem’s business prospects, revenue streams, and financial results.

Immediately following the closing of the business combination in April 2021, shares of Stem’s stock traded as high as $36.38 per share. As further detailed in the complaint, however, Stem soon began reporting financial results that were dramatically worse than the company’s previously issued guidance. Following these disclosures, shares of Stem’s stock declined $28.08 per share, or over 75% in value, to close at $8.30 per share on February 16, 2023.

The investigation seeks to determine whether the members of Stem’s board of directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct.


Current Stem stockholders who purchased or acquired


their shares



prior to December 4, 2020



are encouraged to contact Kaskela Law LLC


(D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by email (



[email protected]



/



[email protected]



) or online at



https://kaskelalaw.com/cases/stem/



, for additional information about this investigation and their legal rights and options.

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com. This notice may constitute attorney advertising in certain jurisdictions.

CONTACT:

KASKELA LAW LLC

D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750
www.kaskelalaw.com



Delta Corp Holdings Limited Advances Merger and Share Exchange with Coffee Holding Co., Inc. with Filing of Registration Statement

NEW YORK and LONDON, Sept. 28, 2023 (GLOBE NEWSWIRE) — Coffee Holding Co., Inc. (NASDAQ: JVA) (“Coffee Holding”), a publicly traded integrated wholesale coffee roaster and dealer located in the United States, and Delta Corp Holdings Limited (“Delta”), a privately held holding company engaged in logistics, fuel supply and asset management related services, primarily servicing the international supply chains of commodity, energy and capital goods producers, jointly announced the filing with the U.S. Securities and Exchange Commission (“SEC”) of a registration statement on Form F-4 by Delta Corp Holdings Limited, a newly created holding company incorporated under the laws of the Cayman Islands (“Pubco”). The registrant Pubco is also referred to as Delta Corp Holdings Limited or Delta Corp Holdings Ltd.

As previously announced, on September 30, 2022, Coffee Holding entered into a merger and share exchange agreement (the “definitive agreement”), dated September 29, 2022, with Delta, whereby Coffee Holding and Delta will each become wholly owned subsidiaries of Pubco. The closing of the transactions contemplated by the definitive agreement is subject to certain conditions, including, without limitation, the approval of the stockholders of Coffee Holding and the approval of the listing of the ordinary shares of Pubco on the Nasdaq Stock Market. Delta shareholders will become the majority shareholders of Pubco following these transactions.

About Coffee Holding

Founded in 1971, Coffee Holding is a leading integrated wholesale coffee roaster and dealer in the United States and one of the few coffee companies that offers a broad array of coffee products across the entire spectrum of consumer tastes, preferences and price points. Coffee Holding’s product offerings consist of eight proprietary brands, each targeting a different segment of the consumer coffee market as well as roasting and blending coffees for major wholesalers and retailers throughout the United States who want to have products under their own names to compete with national brands. In addition to selling roasted coffee, Coffee Holding also imports green coffee beans from around the world which it resells to smaller regional roasters and coffee shops throughout the United States and Canada.

About Delta

Delta is a fully integrated global business engaged in logistics, fuel supply and asset management related services, primarily servicing the international supply chains of commodity, energy, and capital goods producers. Delta operates its business through three segments: Bulk Logistics, Energy Logistics and Asset Management. Delta’s Bulk Logistics division is an asset-light third-party logistics provider of freight forwarding, ocean transportation, mine-to-port, and related services connecting producers of commodities, agriculture products, capital goods and energy to end users. Delta’s Energy Logistics operations provides its customers with industry leading fuels, lubricants and carbon offset products with a focus on environmental impact. Delta also offers Asset Management services to the marine transportation and offshore oil and gas industries. Delta’s business model is asset-light, and its service offerings facilitate the global trade of energy, raw materials, intermediate goods, and agricultural products. Delta is a multinational business with offices throughout Europe, the Middle East, Africa and Asia. For more information, please see Delta’s website at www.wearedelta.com.

Additional Information and Where to Find It

In connection with the proposed business combination, Pubco (named Delta Corp Holdings Limited or Delta Corp Holdings Ltd) has filed a registration statement on Form F-4 to the SEC (as amended, the “Registration Statement”), which includes a preliminary prospectus with respect to Pubco’s securities to be issued in connection with the proposed business combination and a preliminary proxy statement to be distributed to holders of JVA’s common stock in connection with JVA’s solicitation of proxies for the vote by JVA’s stockholders with respect to the proposed business combination and other matters to be described in the Registration Statement. The Registration Statement has not been declared effective by the SEC. After the Registration Statement is declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to stockholders of JVA as of the record date in the future to be established for voting on the proposed business combination and will contain important information about the proposed business combination and related matters. INVESTORS AND SECURITY HOLDERS OF JVA, PUBCO AND OTHER INTERESTED PERSONS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT HAVE BEEN OR WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. Security holders and other interested persons may obtain free copies of the Registration Statement, preliminary proxy statement/prospectus, definitive proxy statement/prospectus, and other relevant material (in each case when available) at the website maintained by the SEC at www.sec.gov. or by directing a request to: Coffee Holding Co., Inc. 3475 Victory Boulevard, Staten Island, New York 10314, Attn: Andrew Gordon, Chief Executive Officer.

Participants in the Solicitation

Coffee Holding, Delta, Pubco and each of their directors,, executive officers and certain other members of management and employees may, under SEC rules, be deemed to be participants in the solicitation of proxies from the stockholders of Coffee Holding with respect to the proposed transaction and related matters. Information about the directors and executive officers of Coffee Holding, including their ownership of shares of Coffee Holding common stock, is included in Coffee Holding’s Annual Report on Form 10-K for the year ended October 31, 2022, which was filed with the SEC on March 29, 2023. Additional information regarding the persons or entities who may be deemed participants in the solicitation of proxies from Coffee Holding stockholders, including a description of their interests in the proposed business combination by security holdings or otherwise, is included in the Registration Statement’s proxy statement/prospectus and other relevant documents filed or to be filed with the SEC by Pubco, or Coffee, when they become available. You may obtain free copies of these documents as described above.

No Offer or Solicitation

This communication is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such other jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between Pubco, Coffee Holding and Delta. All statements other than statements of historical facts contained in this press release, including statements regarding Pubco’s, Coffee Holding’s or Delta’s future results of operations and financial position, Pubco’s, Coffee Holding’s and Delta’s business strategy, prospective costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated operations of Pubco, Coffee Holding and Delta, and the expected value of the combined company after the transactions, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to, the following risks relating to the proposed transaction: the occurrence of any event, change or other circumstances that could give rise to the termination of the transaction agreement; the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of Coffee Holding’s securities; the occurrence of any event, change or other circumstances that could give rise to the termination of the transaction agreement; the inability to complete the transactions contemplated by the transaction agreement, including due to failure to obtain approval of the stockholders of Coffee Holding or other conditions to closing in the definitive agreement; the inability to obtain or maintain the listing of Pubco ordinary shares on Nasdaq following the proposed transaction; the risk that the proposed transaction disrupts current plans and operations of Coffee Holding as a result of the announcement and consummation of the proposed transaction; the ability to recognize the anticipated benefits of the proposed transaction, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth economically and hire and retain key employees; costs related to the proposed transaction; changes in applicable laws or regulations; the possibility that Pubco, Delta or Coffee Holding may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in the proxy statement/prospectus (when available) relating to the proposed transaction, including those under “Risk Factors” therein, and in other filings with the SEC made by Pubco and Coffee Holding. There can be no assurance of the completion of the proposed business combination, nor subject to and following such completion, the realization of potential benefits of the proposed business combination. Moreover, Pubco, Delta and Coffee Holding operate in very competitive and rapidly changing environments. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Pubco’s, Delta’s and Coffee Holding’s control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, Pubco, Delta and Coffee Holding assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. None of Pubco, Delta or Coffee Holding gives any assurance that either Delta or Coffee Holding or Pubco will achieve its expectations.

For further information, contact:

Coffee Holding Co., Inc.

Andrew Gordon
President & CEO
(718) 832-0800

Delta Corp Holdings Limited

Joseph Nelson
Chief Financial Officer
Phone: +44 0203 753 5598
Email: [email protected]



Enphase Energy Releases its Solargraf Design and Proposal Software Platform in Germany and Austria

FREMONT, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world’s leading supplier of microinverter-based solar and battery systems, today announced that Solargraf℠, its cloud-based design and proposal software platform, is now available in Germany and Austria. The Solargraf platform is used by solar installers for creating production system designs and proposals for both residential and commercial customers and is also currently available to solar installers in the United States, Canada, and Brazil.

The key features available to installers in Germany and Austria include:

  • Three-dimensional (3D) modeling. The Solargraf platform offers an artificial intelligence-based 3D modeling tool for solar and battery systems that will automatically detect obstructions, intelligently optimize panel placement, and provide accurate shading analysis, all with one click.
  • A built-in bill of materials (BOM) calculator. An integrated calculator that empowers installers who manage job costs and margins based on actual bills of materials in addition to per-watt pricing models.
  • E-signature support via DocuSign™. The Solargraf platform now supports DocuSign’s industry-leading document management and e-signature completion, including customizable form fields and legal disclaimers.
  • Enphase microinverter and solar panel pairing. The Solargraf platform provides a feature to help match the right Enphase microinverter with various solar panels to ensure maximum system performance.

“The Solargraf platform gives us the opportunity to create a detailed and individual plan for our customers,” said Sven Schöttler, manager of e-commerce and logistics at WHT International GmbH, an installer of Enphase products in Germany. “The visual and content output from the platform offers our customers real added value and gives us a decisive advantage over our competitors. The tool also actively supports our business operations from planning to preparing the offer to the conclusion of the purchase.”

“The Solargraf solution makes solar planning quick and simple using available technology and data to make our lives as easy as possible,” said Norbert Gabriel, owner of Elektrohaus GABRIEL GmbH, an installer of Enphase products in Austria. “The tool provides us with quick precision designs and offers an interactive and appealing proposal for our customers. The setup is fantastic.”

Enphase’s all-in-one system design and proposal tool is built specifically to simplify and accelerate the end-to-end sales and installation process for solar professionals. The Solargraf software platform provides solar installers with critical pre-sales customer engagement via designs, price quoting, and workflow management from any PC, tablet, or mobile device.

“The Solargraf platform improves our ability to meet growing customer demand for solar and battery storage,” said Volkan Kuyumcuoglu, general manager at Solarhyp, an installer of Enphase products in Germany. “The tool’s streamlined tool enables our teams to quickly and accurately present our clients with a best-in-class energy independence design and sales proposal.”

“We appreciate the simple experience that the Solargraf platform can offer our customers, helping to further streamline our business,” said Hannes Tumfart, solar energy systems integration specialist at HalloSonne GmbH, an installer of Enphase products in Austria. “The tool enables us to build a solar energy system that is designed to maximize value for our customers.”

“Enphase continues to improve and expand the Solargraf platform to meet the evolving needs of installers and their customers,” said Jayant Somani, vice president and general manager of the digital business unit at Enphase Energy. “The Solargraf software platform, in addition to Enphase’s industry leading microinverter and battery products, provides installers in Germany and Austria with the end-to-end tools and technology they need to efficiently design high-performance, customized systems and complete proposals that meet their customers’ needs. As demand for energy independence grows in the region, Enphase installers will be equipped to better serve their growing customer base and reduce soft costs.”

The Solargraf software platform is expected to be released in more international markets later this year. For more information about the platform in Germany and Austria, please visit the website.

About Enphase Energy, Inc.

Enphase Energy, a global energy technology company based in Fremont, CA, is the world’s leading supplier of microinverter-based solar and battery systems that enable people to harness the sun to make, use, save, and sell their own power—and control it all with a smart mobile app. The company revolutionized the solar industry with its microinverter-based technology and builds all-in-one solar, battery, and software solutions. Enphase has shipped approximately 68 million microinverters, and more than 3.5 million Enphase-based systems have been deployed in over 145 countries. For more information, visit https://www.enphase.com and follow the company on Facebook, LinkedIn and X (formerly Twitter).

©2023 Enphase Energy, Inc. All rights reserved. Enphase, the “e” logo, IQ, and certain other marks listed at https://enphase.com/trademark-usage-guidelines are trademarks or service marks of Enphase Energy, Inc. in the United States and other countries. Other names are for informational purposes and may be trademarks of their respective owners.

Forward-Looking Statements

This press release may contain forward-looking statements, including statements related to the expected capabilities and performance of Enphase Energy’s technology and products, including safety, quality and reliability; the availability and market adoption of Enphase products; and the demand for energy independence. These forward-looking statements are based on Enphase’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of certain risks and uncertainties, including those risks described in more detail in Enphase’s most recently filed Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, its Annual Report on Form 10-K for the year ended December 31, 2022 and other documents on file with the SEC from time to time, which are available on the SEC’s website at https://www.sec.gov/. Enphase Energy undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, or changes in its expectations, except as required by law.

Contact:

Enphase Energy
[email protected]



ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) — ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced that Daniel A. de Boer, Founder and CEO, will participate in the ADAR Editing Panel at the Chardan 7th Annual Genetic Medicines Conference in New York City. The panel is scheduled for October 2, 2023 at 9:30 am – 10:15 am EDT, and a recording of the session will be made available on the Company’s website after the conference. ProQR will also participate in 1×1 investor meetings.

For more information about the conference, please contact your Chardan representative.

About Axiomer®

ProQR is pioneering a next-generation RNA base editing technology called Axiomer®, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer® “Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer® EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) – correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer®, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.

Learn more about ProQR at www.proqr.com.

Forward Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our participation in this conference, our business, our technology, our strategy, our Axiomer platform, and our product candidates and their therapeutic potential. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners; the likelihood of our preclinical and clinical programs being initiated and executed on timelines provided and reliance on our contract research organizations and predictability of timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our reliance on contract manufacturers to supply materials for research and development and the risk of supply interruption from a contract manufacturer; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners, including the collaboration with Lilly; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; and general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

ProQR Therapeutics N.V.

Investor contact:

Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
[email protected]
or
Hans Vitzthum
LifeSci Advisors
T: +1 617 430 7578
[email protected]

Media contact:

Robert Stanislaro
FTI Consulting
T: +1 212 850 5657
[email protected]